The adverse antitrust verdict creates material downside risk to FY2025 reported earnings once the amount is quantified. Monitor for the revised earnings report filing for the specific dollar impact. The company's statement that FY2026 guidance is not materially impacted provides some cushion, but the lack of disclosed amount keeps uncertainty elevated.
Price Chart
Executive Summary
Takeda discloses that a May 18, 2026 jury verdict in the AMITIZA antitrust litigation constitutes an adjusting subsequent event for its FY2025 IFRS consolidated earnings report. The company plans to record the impact and file a revised earnings report with the Tokyo Stock Exchange once the amount is determined, but does not expect its FY2026 forecast to be materially impacted. The financial magnitude of the verdict is not disclosed.
Key Facts
- A jury verdict was returned on May 18, 2026 in the AMITIZA (lubiprostone) antitrust litigation in the U.S. District Court for the District of Massachusetts.
- The verdict is an adjusting subsequent event for the FY2025 IFRS consolidated earnings report announced May 13, 2026.
- Takeda will record the impact and file a revised earnings report with the Tokyo Stock Exchange once the impact is determined.
- Takeda does not expect its FY2026 financial forecast or Management Guidance to be materially impacted.
- The dollar amount of the verdict is not disclosed in the filing.
Financial Impact
Undisclosed — the jury verdict amount is not stated in the filing. The impact will be recorded in revised FY2025 IFRS financials.
Risk Factors
- Potential material charge to FY2025 earnings from the jury verdict, amount unknown.
- Risk of additional litigation or settlement costs beyond the initial verdict.
- Reputational and competitive risk from antitrust findings in a key drug market.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001395064-26-000154 |
| Document: planne1.htm | 0001395064-26-000154 |
| Document: 0001395064-26-000154-index-headers.html | 0001395064-26-000154 |
| Document: 0001395064-26-000154-index.html | 0001395064-26-000154 |
| Document: 0001395064-26-000154.txt | 0001395064-26-000154 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jun 9, 2026 19w ago | 6-K | $31.30 $32.48 | ▲ +3.77% | ▲ +1.97% | $41.22 (+31.69%) |
Jun 5, 2026 20w ago | 6-K | $30.47 $34.28 | ▼ −12.50% | ▼ −11.93% | $41.22 (−35.28%) |
Jun 5, 2026 20w ago | 6-K | $30.47 $34.28 | ▼ −12.50% | ▼ −11.93% | $41.22 (−35.28%) |
Jun 1, 2026 21w ago | 6-K | $30.47 $30.47 | · 0.00% | ▲ +2.75% | $41.22 (+35.28%) |
May 26, 2026 21w ago | 6-K | $32.10 $30.47 | ▼ −5.08% | ▼ −6.29% | $41.22 (+28.41%) |
May 26, 2026 21w ago | 6-K | $32.10 $30.47 | ▼ −5.08% | ▼ −6.29% | $41.22 (+28.41%) |
May 26, 2026 21w ago | 6-K | $32.10 $30.47 | ▼ −5.08% | ▼ −6.29% | $41.22 (+28.41%) |
May 26, 2026 21w ago | 6-K | $32.10 $30.47 | ▲ +5.08% | ▲ +6.29% | $41.22 (−28.41%) |
May 19, 2026 22w ago | 6-K | $32.26 $32.10 | ▲ +0.50% | ▲ +2.79% | $41.22 (−27.77%) |
May 13, 2026 23w ago | 6-K | $32.68 $32.26 | ▼ −1.29% | ▼ −0.13% | $41.22 (+26.13%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers